Clinical characterization of patients with primary aldosteronism plus subclinical Cushing’s syndrome

BMC Endocrine Disorders

Table 4 Multiple regression analysis on maximum tumor diameter and serum potassium concentration with respect to patients in the PA, SCS, and PASCS groups who had a unilateral adrenal tumor (n = 65)

	Crude model			Adjusted model^a
	Difference	(95% CI)	P value	Difference	(95% CI)	P value
MTD, cm
PASCS (n = 12^b)	Reference			Reference
PA (n = 41^c)	−1.24	(– 1.70 to −0.78)	< 0.001	– 1.19	(– 1.66 to − 0.72)	< 0.001
SCS (n = 12)	−0.04	(– 0.58 to 0.57)	NS	– 0.01	(– 0.55 to 0.54)	NS
Serum potassium concentration, mEq/L
PASCS (n = 12^b)	Reference			Reference
PA (n = 41^c)	0.23	(−0.23 to 0.69)	NS	0.24	(−0.25 to 0.72)	NS
SCS (n = 12)	0.96	(0.38 to 1.53)	< 0.005	0.97	(0.38 to 1.54)	< 0.005

^aConsists of 65patients who had a unilateral adrenal tumor (41, 12, and 12 patients with PA, SCS, and PASCS, respectively). All the models were adjusted for age, sex, and BMI at the time of diagnosis
^bThe numbers of patients who remained after the exclusion of 2 patients who had bilateral tumors and who missed the maximum tumor diameter
^cThe numbers of patients who remained after the exclusion of the following patients who missed the maximum tumor diameter: 1 patient who had a unilateral adrenal tumor and 3 patients who had bilateral adrenal tumors
PA primary aldosteronism, SCS subclinical Cushing’s syndrome, NS not significant, PASCS primary aldosteronism plus subclinical Cushing’s syndrome, CI confidence interval, MTD maximum tumor diameter

ISSN: 1472-6823